metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Interpretación y consideraciones metodológicas y estadísticas en los estudios...
Journal Information
Vol. 26. Issue S12.
Raltegravir: el primer inhibidor de la integrasa del VIH
Pages 47-52 (November 2008)
Share
Share
Download PDF
More article options
Vol. 26. Issue S12.
Raltegravir: el primer inhibidor de la integrasa del VIH
Pages 47-52 (November 2008)
Full text access
Interpretación y consideraciones metodológicas y estadísticas en los estudios de rescate
Interpreting methodological and statistical considerations in studies of rescue therapy
Visits
1923
Federico Pulidoa,
Corresponding author
pulidof@gmail.com

Correspondencia: Unidad VIH. Hospital 12 de Octubre. Avda. de Córdoba, s/n. 28041 Madrid. España.
, Asunción Hernandob
a Unidad VIH. Hospital Universitario 12 de Octubre. Madrid. España
b Departamento de Especialidades Médicas. Universidad Europea de Madrid. Villaviciosa de Odón. Madrid. España
This item has received
Article information

La metodología utilizada en los estudios de tratamiento de rescate en ocasiones es compleja. Esto se debe a la heterogeneidad de objetivos y opciones. En primer lugar la definición de fracaso está sujeta a múltiples interpretaciones y matices. En segundo lugar, el objetivo a lograr en el tratamiento de estos pacientes ha variado en función de las opciones de tratamiento existentes en cada caso y en cada momento. Por último, la metodología utilizada para desarrollar los estudios de tratamiento de rescate ha ido variando con el tiempo, a la par que han cambiado los objetivos y las opciones. En estos momentos es esperable un nuevo cambio para ajustarnos a la situación actual, ya que el número de opciones terapéuticas para el tratamiento de rescate se ha incrementado de forma considerable en el último año. En la presente revisión se comenta cómo ha ido cambiando el diseño de estos estudios, los principales aspectos metodológicos a considerar y las recomendaciones de las agencias al respecto.

Palabras clave:
Metodología
Tratamiento de rescate
Tratamiento antirretroviral

The methodology used in studies of rescue therapy is sometimes complex. This is because of the heterogeneity of objectives and options. Firstly, the definition of failure has multiple interpretations and subtle distinctions. Secondly, the aim of treatment in these patients has varied according to the available treatment options in each case and at each moment of time. Lastly, the methodology used to develop these studies of rescue therapy has varied over time in line with changes in their aims and options. Currently, a new change can be expected to adjust to the current situation, since the number of therapeutic options for rescue therapy has substantially increased in the last year. The present review discusses changes in the design of these studies, the main methodological issues to be taken into account and the recommendations on this subject.

Key words:
Methodology
Rescue therapy
Antiretroviral therapy
Full text is only aviable in PDF
Bibliografía
[1.]
Panel de expertos de Gesida/PNS.
Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2007).
Enferm Infecc Microbiol Clin, 25 (2007), pp. 32-53
[2.]
D. Moher, K.F. Schulz, D.G. Altman.
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.
Lancet, 357 (2001), pp. 1191-1194
[3.]
ICH Harmonised Tripartite Guideline.
Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group.
Stat Med, 18 (1999), pp. 1905-1942
[4.]
F.H. Messerli.
ALLHAT, or the soft science of the secondary end point.
Ann Intern Med, 139 (2003), pp. 777-780
[5.]
E. Losina, R. Islam, A.C. Pollock, P.E. Sax, K.A. Freedberg, R.P. Walensky.
Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview.
Clin Infect Dis, 38 (2004), pp. 1613-1622
[6.]
J.P. Lalezari, K. Henry, M. O’Hearn, J.S. Montaner, P.J. Piliero, B. Trottier, et al.
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
N Engl J Med, 348 (2003), pp. 2175-2185
[7.]
A. Lazzarin, B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, et al.
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
N Engl J Med, 348 (2003), pp. 2186-2195
[8.]
R. Elston, P. Yates, M. Tisdale, N. Richards, S. White, E. DeJesus.
GW433908/ritonavir: 48 weeks results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype.
Program and Abstracts of the XIV International AIDS Conference, Bangkok,
[9.]
M. Johnson, B. Grinsztejn, C. Rodriguez, J. Coco, E. DeJesus, A. Lazzarin, et al.
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
AIDS, 19 (2005), pp. 685-694
[10.]
S. Kaul, G.A. Diamond.
Good enough: a primer on the analysis and interpretation of noninferiority trials.
Ann Intern Med, 145 (2006), pp. 62-69
[11.]
W.L. Greene, J. Concato, A.R. Feinstein.
Claims of equivalence in medical research: are they supported by the evidence?.
Ann Intern Med, 132 (2000), pp. 715-722
[12.]
P. Alderson.
Absence of evidence is not evidence of absence.
[13.]
EMEA. The European Agency for the Evaluation of Medical Products. Committee for proprietary medicinal products. Points to consider on switching between superiority and non-inferiority. CPMP/EWP/482/99 2000.
[14.]
FDA. U.S. Department of Health and Human Services. Center for Drug Evaluation and Research. Guidance for Industry. Antiretroviral Drugs Using Plasma HIV RNA Measurements — Clinical Considerations for Accelerated and Traditional Approval. Octubre 2002.
[15.]
D. Cooper, J. Gatell, J. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, et al.
Resultados a las 48 semanas de BENCHMRK-1, un estudio en fase III de raltegravir (RAL) en pacientes con fracaso del tratamiento antirretroviral (TAR) y VIH-1 resistente a las tres clases de medicamentos.
Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections,
[16.]
R. Steigbigel, P. Kumar, J. Eron, M. Schechter, M. Markowitz, M. Loutfy, et al.
Resultados a las 48 semanas de BENCHMRK-2, un estudio en fase III de raltegravir (RAL) en pacientes con fracaso del tratamiento antirretroviral (TAR) y VIH-1 resistente a las tres clases de medicamentos.
Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections,
[17.]
J. Lalezari, J. Goodrich, E. DeJesus, H. Lampiris, R. Gulick, M. Saag, et al.
Efficacy and Safety of Maraviroc plus Optimized Background Therapy In Viremic, ART-Experienced Patients Infected With CCR5-Tropic HIV-1: 24-Week. Motivate 1 Study.
Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections,
[18.]
M. Nelson, G. Fätkenheuer, I. Konourina, A. Lazzarin, N. Clumeck, A. Horban, et al.
Efficacy and Safety of Maraviroc plus Optimized Background Therapy In Viremic, ART-Experienced Patients Infected With CCR5-Tropic HIV-1: 24-Week. Motivate 2 Study.
Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections,
[19.]
J. Gathe, D.A. Cooper, C. Farthing, D. Jayaweera, D. Norris, G Pierone Jr, et al.
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatmentexperienced patients: 24-week analysis from the RESIST-1 trial.
Clin Infect Dis, 43 (2006), pp. 1337-1346
[20.]
P. Cahn, J. Villacian, A. Lazzarin, C. Katlama, B. Grinsztejn, K. Arasteh, et al.
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
Clin Infect Dis, 43 (2006), pp. 1347-1356
[21.]
C. Katlama, R. Esposito, J.M. Gatell, J.C. Goffard, B. Grinsztejn, A. Pozniak, et al.
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
[22.]
B. Clotet, N. Bellos, J.M. Molina, D. Cooper, J.C. Goffard, A. Lazzarin, et al.
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Lancet, 369 (2007), pp. 1169-1178
[23.]
J.V. Madruga, P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari, A. Mills, et al.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
[24.]
A. Lazzarin, T. Campbell, B. Clotet, M. Johnson, C. Katlama, A. Moll, et al.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, doubleblind, placebo-controlled trial.
[25.]
EMEA. The European Agency for the Evaluation of Medical Products. Committee for medicinal products for human use. Guideline on the clinical development of medicinal products for the treatment of HIV infection. Draft. EMEA/CPMP/EWP/633/02 Rev. 2 October 2007.
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos